Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Symbicort COPD approval (correction)

Executive Summary

AstraZeneca's Symbicort 160/4.5 mcg is now approved for the twice-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease, including bronchitis and emphysema, with twice-daily inhalations, like GlaxoSmithKline's Advair 250/50 mcg. The original version of this story incorrectly reported Symbicort's indication and Advair's dosing (1"The Pink Sheet," March 9, 2009, p. 23). Also, AstraZeneca clarified that it will not promote Symbicort based on its risk profile and offered pricing data that differ from the estimates offered by a Decision Resources analyst in the story - the wholesale acquisition cost of Symbicort is listed as $5.87/day while the WAC for Advair is $6.35/day

You may also be interested in...

AstraZeneca’s Symbicort On Advair’s Heels With COPD Approval

Symbicort's rapid onset of action and lack of pneumonia signal could be competitive advantages as the drug enters the market with its newly approved use for chonic obstructive pulmonary disease

EU’s SCCS Finds Endocrine-Disrupting Evidence Inconclusive In UV Filter Reassessments

While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.

US FDA Urges COVID-19 Transmission Risk Mitigation In Cell And Gene Therapy Manufacturing

The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts